The relationship between muscle pain and fatigue.

Neuromuscul Disord

Australian Neuro-Muscular Research Institute and Centre for Neuromuscular and Neurological Disorders, University of Western Australia, Queen Elizabeth II Medical Centre, Perth, WA, Australia.

Published: December 2012

AI Article Synopsis

  • Pain and fatigue can occur simultaneously during intense muscle activity, impacting overall muscle performance, especially in individuals with neuromuscular disorders who may experience chronic pain.
  • Some patients with conditions like fibromyalgia and metabolic myopathies suffer from both myofascial and contraction-induced pain, which may hinder their ability to exercise effectively.
  • Research methods like transcranial magnetic brain stimulation are shedding light on how pain and fatigue affect motor function, indicating potential for these techniques to help manage fatigue and pain in patients with neuromuscular disorders.

Article Abstract

Pain and fatigue may occur together during sustained exhausting muscle contractions, particularly as the limit of endurance is approached, and both can restrict muscle performance. Patients with neuromuscular disorders may have chronic myofascial pain (e.g. fibromyalgia) or contraction-induced pain (e.g. in metabolic myopathies). In some patients these two types of pain may coexist and both may inhibit central motor drive during exercise. Little is known about the central motor adaptations that occur in patients with neuromuscular disorders and how the effects of pain are mediated. Transcranial magnetic brain stimulation has made it possible to investigate the changes in excitability of the central motor pathway during fatiguing muscle activity and have thrown light on the mechanisms of fatigue in normal subjects and individuals with chronic fatigue syndrome and multiple sclerosis, but there have been few studies in patients with neuromuscular disorders. Repetitive magnetic brain stimulation protocols can now be used to modulate the excitability of the motor system during exercise to delay the onset of peripheral fatigue, and to reduce chronic pain. The possible application of these techniques in patients with neuromuscular disorders warrants further investigation.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nmd.2012.10.003DOI Listing

Publication Analysis

Top Keywords

patients neuromuscular
16
neuromuscular disorders
16
central motor
12
pain fatigue
8
magnetic brain
8
brain stimulation
8
pain
7
fatigue
5
patients
5
relationship muscle
4

Similar Publications

Pediatric Sleep Quality and Parental Stress in Neuromuscular Disorders: Descriptive Analytical Study.

Asian Pac Isl Nurs J

January 2025

Nursing Care Research Center, Clinical Sciences Institute, Nursing Faculty, Baqiyatallah University of Medical Sciences, Vanak Square, Tehran, Iran, 98 9127297199.

Background: Neuromuscular disorders (NMDs) constitute a heterogeneous group of disorders that affect motor neurons, neuromuscular junctions, and muscle fibers, resulting in symptoms such as muscle weakness, fatigue, and reduced mobility. These conditions significantly affect patients' quality of life and impose a substantial burden on caregivers. Spinal muscular atrophy (SMA) is a relatively common NMD in children that presents in various types with varying degrees of severity.

View Article and Find Full Text PDF

Motor neuron diseases are not exclusively motor; the SSR paradigm.

Amyotroph Lateral Scler Frontotemporal Degener

January 2025

2nd Second Department of Neurology, National and Kapodistrian University of Athens, School of Medicine, Attikon University Hospital, Athens, Greece.

Motor Neuron Diseases (MNDs), familial and sporadic, are progressive neurodegenerative disorders that, for an extended period in the past, were considered purely motor disorders. During the course of the disease, however, some patients exhibit concomitant non-motor signs; thus, MNDs are currently perceived as multisystem disorders. Assessment of non-motor symptoms is usually performed clinically, although laboratory tests can also be routinely used to objectively evaluate these symptoms.

View Article and Find Full Text PDF

Background: Neuromuscular blocking agents (NMBAs) are routinely used in anesthesia practice. An undetected, incomplete recovery of neuromuscular function at the end of surgery potentially exposes patients to clinical deterioration in the postoperative period. The aim of this study was to investigate the incidence of postoperative residual neuromuscular blockade (RNMB) in a cohort of patients receiving NMBAs.

View Article and Find Full Text PDF

Evaluation of professional practices in the use of mexiletine for the management of childhood myotonia in French pediatric neuromuscular centers (MEXI-PEDI survey).

Arch Pediatr

January 2025

CMR Neuromusculaire, Service de génétique médicale, Hôpital Estaing, CHU de Clermont-Ferrand, Clermont-Ferrand, France. Electronic address:

Background: Myotonia is the main feature of both myotonic dystrophy (DM) and non-dystrophic myotonia (NDM). It is felt as stiffness, pain, fatigue, and weakness. In France, mexiletine, a non-selective voltage-gated sodium channel blocker, is approved for the treatment of myotonia in adults with NDM, and it has a temporary recommendation for use in the symptomatic treatment of DM in adults.

View Article and Find Full Text PDF

Usefulness of serum neurofilament light chain in chronic inflammatory demyelinating polyradiculoneuropathy.

J Neurol Sci

January 2025

Neuromuscular Diseases Unit, Department of Neurology, Vall d'Hebron University Hospital, Vall d'Hebron Research Institute, Barcelona, Spain; Department de Medicina, Universitat Autónoma de Barcelona, Barcelona, Spain.

Background: The development of new biomarkers is essential to improve diagnostic accuracy and guide treatment decisions in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). The aim of this study was to investigate the utility of the serum neurofilament light chain (sNfL) level as a marker for disability and response to immunomodulatory treatment in patients with CIDP.

Methods: This prospective, single-center, observational study included 38 patients with CIDP: 19 treatment-naive (CIDP-I) patients assessed before and after the initiation of immunomodulatory therapy and 19 stable patients on maintenance immunoglobulins (CIDP-M).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!